Oculis(OCSAW)
ZUG, SwitzerlandBiotechnology
Focus: Oculis is a Switzerland-based biotech focused on dexamethasone-based ophthalmic therapeutics for diabetic macular edema, uveitis, and inflammatory eye conditions. The company operates at public-stage scale with 5,000+ employees and is positioned as a specialist player in ophthalmology.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
5000+
Open Jobs
0
About Oculis
AI assessmentNot HiringNo open roles listed right now. Follow Oculis to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Dexamethasone ophthalmic suspension
Growing
Growth
Multiple Phase 2–3 development pathways (suspension + nanoparticles) indicate aggressive development for a major ophthalmology market.
Help build intelligence for Oculis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.